{"id":79023,"topic":"peptides","source":"BioPharma APAC","title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","url_hash":"20b8ba8082c363256e01ea9d6dee9dfdf41c2b56","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk1NX1EtdmRiNkRkODE3ZEc1Tlp2SHlTQkw4bGpJMTZUT2NoUzNVN3pUcHBrVVlOSklpRlJyR3Uta2VRendvTUxTaWVNbVRMZkktOVBKZ2hXcHhzUENJRllWYWVSS29VRGJhQkNYVDg1MGRDSzF1Q1NrQTFFdm5LV2l1ZDQxRFl5M25xTFJ3WnJsZXlQRmtZeG1xc2pES0pPel9iU0dqYXhiVlV6VUZpclBvRTZVUlVP?oc=5\" target=\"_blank\">Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma APAC</font>","content":null,"image_url":null,"lang":"en","published_at":"2026-09-10T00:22:30+00:00","fetched_at":"2026-09-10T01:15:09+00:00","status":"read","starred":0,"extract_state":"failed","summary_auto":null,"cluster_id":null,"extract_retries":2,"extract_error":"trafilatura_none","contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":453,"usable_text_length":453,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":453}},"news_item":{"id":79023,"canonical_url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","source_url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","source_name":"BioPharma APAC","author":null,"published_at":"2026-09-10T00:22:30+00:00","locale":"en","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk1NX1EtdmRiNkRkODE3ZEc1Tlp2SHlTQkw4bGpJMTZUT2NoUzNVN3pUcHBrVVlOSklpRlJyR3Uta2VRendvTUxTaWVNbVRMZkktOVBKZ2hXcHhzUENJRllWYWVSS29VRGJhQkNYVDg1MGRDSzF1Q1NrQTFFdm5LV2l1ZDQxRFl5M25xTFJ3WnJsZXlQRmtZeG1xc2pES0pPel9iU0dqYXhiVlV6VUZpclBvRTZVUlVP?oc=5\" target=\"_blank\">Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma APAC</font>","full_text":null,"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk1NX1EtdmRiNkRkODE3ZEc1Tlp2SHlTQkw4bGpJMTZUT2NoUzNVN3pUcHBrVVlOSklpRlJyR3Uta2VRendvTUxTaWVNbVRMZkktOVBKZ2hXcHhzUENJRllWYWVSS29VRGJhQkNYVDg1MGRDSzF1Q1NrQTFFdm5LV2l1ZDQxRFl5M25xTFJ3WnJsZXlQRmtZeG1xc2pES0pPel9iU0dqYXhiVlV6VUZpclBvRTZVUlVP?oc=5\" target=\"_blank\">Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma APAC</font>","extraction":{"state":"failed","confidence":0.2,"error":"trafilatura_none","explanation":"Low confidence: extractor returned no usable article text.","diagnostics_url":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":453,"usable_text_length":453,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":453}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","summary":"<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk1NX1EtdmRiNkRkODE3ZEc1Tlp2SHlTQkw4bGpJMTZUT2NoUzNVN3pUcHBrVVlOSklpRlJyR3Uta2VRendvTUxTaWVNbVRMZkktOVBKZ2hXcHhzUENJRllWYWVSS29VRGJhQkNYVDg1MGRDSzF1Q1NrQTFFdm5LV2l1ZDQxRFl5M25xTFJ3WnJsZXlQRmtZeG1xc2pES0pPel9iU0dqYXhiVlV6VUZpclBvRTZVUlVP?oc=5\" target=\"_blank\">Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma APAC</font>","source":"BioPharma APAC","date":"2026-09-10T00:22:30+00:00","content":"","confidence":0.2,"diagnostics_url":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","quality_bucket":"low","failure_kind":"extractor_empty","retryable":false,"quality_reason":"Low confidence: extractor returned no usable article text.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":453,"usable_text_length":453,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":453}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/79023","export_markdown":"/api/items/79023/export?format=markdown","export_json":"/api/items/79023/export?format=json","diagnose":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html"},"formats":{"full":{"id":79023,"title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","source":"BioPharma APAC","author":null,"published_at":"2026-09-10T00:22:30+00:00","locale":"en","topic":"peptides","tags":[],"excerpt":"<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk1NX1EtdmRiNkRkODE3ZEc1Tlp2SHlTQkw4bGpJMTZUT2NoUzNVN3pUcHBrVVlOSklpRlJyR3Uta2VRendvTUxTaWVNbVRMZkktOVBKZ2hXcHhzUENJRllWYWVSS29VRGJhQkNYVDg1MGRDSzF1Q1NrQTFFdm5LV2l1ZDQxRFl5M25xTFJ3WnJsZXlQRmtZeG1xc2pES0pPel9iU0dqYXhiVlV6VUZpclBvRTZVUlVP?oc=5\" target=\"_blank\">Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma APAC</font>","full_text":null,"reading_time_min":1,"extraction":{"state":"failed","confidence":0.2,"error":"trafilatura_none","explanation":"Low confidence: extractor returned no usable article text.","diagnostics_url":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":453,"usable_text_length":453,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":453}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":453,"usable_text_length":453,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":453}},"actions":{"read":"/item/79023","export_markdown":"/api/items/79023/export?format=markdown","export_json":"/api/items/79023/export?format=json","diagnose":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html"}},"digest":{"id":79023,"title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","source":"BioPharma APAC","topic":"peptides","published_at":"2026-09-10T00:22:30+00:00","excerpt":"<a…","quality_bucket":"low","quality_reason":"Low confidence: extractor returned no usable article text.","reading_time_min":1,"cluster_id":null},"card":{"display_title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","subtitle":"BioPharma APAC · 2026-09-10","summary":"<a…","badges":["quality:low","issue:extractor_empty"],"links":{"read":"/item/79023","original":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","diagnose":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html"},"quality_warning":"Low confidence: extractor returned no usable article text."},"export":{"title":"Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity - BioPharma APAC","url":"https://biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","summary":"<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk1NX1EtdmRiNkRkODE3ZEc1Tlp2SHlTQkw4bGpJMTZUT2NoUzNVN3pUcHBrVVlOSklpRlJyR3Uta2VRendvTUxTaWVNbVRMZkktOVBKZ2hXcHhzUENJRllWYWVSS29VRGJhQkNYVDg1MGRDSzF1Q1NrQTFFdm5LV2l1ZDQxRFl5M25xTFJ3WnJsZXlQRmtZeG1xc2pES0pPel9iU0dqYXhiVlV6VUZpclBvRTZVUlVP?oc=5\" target=\"_blank\">Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma APAC</font>","source":"BioPharma APAC","date":"2026-09-10T00:22:30+00:00","content":"","confidence":0.2,"diagnostics_url":"/api/diagnose?url=https%3A//biopharmaapac.com/news/31/8417/ascletis-begins-us-phase-i-trial-of-oral-amylin-agonist-asc36-for-obesity.html","quality_bucket":"low","failure_kind":"extractor_empty","retryable":false,"quality_reason":"Low confidence: extractor returned no usable article text.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"low","confidence":0.2,"failure_kind":"extractor_empty","retryable":false,"retry_after_attempts":0,"reason":"Low confidence: extractor returned no usable article text.","operator_guidance":{"severity":"warning","recommended_action":"use_summary_with_caveat","next_step":"Use the available summary only with a visible quality caveat.","operator_label":"Use summary with caveat","can_retry":false,"can_use_summary":true,"diagnostics_required":true},"content_depth":{"contract_version":"content_depth.v1","category":"summary_only","label":"Summary only","has_full_text":false,"has_summary":true,"content_length":0,"summary_length":453,"usable_text_length":453,"source_field":"summary"},"legacy_collapsed":false,"signals":{"extract_state":"failed","extract_error":"trafilatura_none","extract_retries":2,"content_length":0,"summary_length":453}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}